Form 4: Hims & Hers Health CEO Andrew Dudum Reports Stock Transactions
SEC Form 4 Filing
Andrew Dudum, CEO of Hims & Hers Health, reports the vesting and settlement of restricted stock units and related tax withholding.
Summary
- On June 14, 2024, Andrew Dudum, the CEO of Hims & Hers Health, Inc., reported transactions involving Class A Common Stock and Restricted Stock Units (RSUs).
- 176,309 Class A Common Stock were acquired through the vesting of RSUs.
- 97,052 shares of Class A Common Stock were withheld by the issuer to cover tax obligations related to the vesting and settlement of RSUs at a price of $23.75.
- Dudum directly owns 79,257 shares of Class A Common Stock following the reported transactions.
- Dudum indirectly owns shares through various trusts, including the Dudum Family Community Property Trust, Dudum Family Heritage Trust, and several GRATs (Grantor Retained Annuity Trusts).
- The reported transactions also involved the vesting of various tranches of RSUs, including 35,446, 35,242, 7,330, 107, 3,576, 1,789, 18,290, and 74,529 RSUs.
- These RSUs vest in quarterly installments based on service requirements.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions related to executive compensation. The vesting of RSUs is generally a positive sign, but the tax withholding is a neutral event.
Positives
- The vesting of RSUs indicates that performance or service-based milestones have been met.
Negatives
- The withholding of shares to cover tax obligations reduces the number of shares directly received by the CEO.
Industry Context
Form 4 filings are standard practice for company insiders and provide transparency into their transactions, which can be informative for investors.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in financial analysis, with firms like Vickers Stock Research and InsiderScore tracking and analyzing Form 4 filings to gauge market sentiment.
- Comparing the CEO's holdings and transactions to those of executives at similar companies like Teladoc Health (TDOC) or GoodRx (GDRX) can provide context on executive compensation and alignment with shareholder interests.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect the CEO's compensation and alignment with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/15/1997 | Date of Richard M. Dudum Irrevocable 1 U/A |
| July 2, 2015 | Date of Andrew Dudum 2015 Trust |
| 11-1-2021 | Date of AD 2021 GRAT |
| 11-1-2021 | Date of AD 2021 GRAT 2 |
| 8-10-2021 | Date of Dudum Family Heritage Trust UAD |
| 9/7/2022 | Date of AD 2022 GRAT 2 |
| 11-28-2022 | Date of AD 2022 GRAT 3 |
| 9-5-2023 | Date of AD 2023 GRAT |
| June 15, 2022 | First Company Quarterly Vesting Date for some RSUs |
| June 15, 2023 | First Company Quarterly Vesting Date for some RSUs |
| 06/14/2024 | Date of transaction |
| June 15, 2024 | First Company Quarterly Vesting Date for some RSUs |
| 06/18/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.